Top 5 Stocks to Buy Now
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel Free MENS Stock Alerts

Jyong Biotech (MENS) Competitors

Jyong Biotech logo
$1.88 -0.02 (-1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.87 -0.01 (-0.53%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MENS vs. KYTX, STRO, CABA, ARVN, and IMMX

Should you buy Jyong Biotech stock or one of its competitors? MarketBeat compares Jyong Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jyong Biotech include Kyverna Therapeutics (KYTX), Sutro Biopharma (STRO), Cabaletta Bio (CABA), Arvinas (ARVN), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.

How does Jyong Biotech compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Jyong Biotech's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyverna TherapeuticsN/A -81.88% -64.87%
Jyong Biotech N/A N/A N/A

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Kyverna Therapeutics and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Kyverna Therapeutics' score of 0.63 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Kyverna Therapeutics Positive
Jyong Biotech Very Positive

Kyverna Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 255.45%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyverna Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyverna TherapeuticsN/AN/A-$161.31M-$3.28N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

Summary

Kyverna Therapeutics beats Jyong Biotech on 6 of the 10 factors compared between the two stocks.

How does Jyong Biotech compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Sutro Biopharma currently has a consensus price target of $52.44, indicating a potential upside of 71.84%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sutro Biopharma is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jyong Biotech has a net margin of 0.00% compared to Sutro Biopharma's net margin of -154.21%.

Company Net Margins Return on Equity Return on Assets
Sutro Biopharma-154.21% N/A -69.20%
Jyong Biotech N/A N/A N/A

In the previous week, Sutro Biopharma had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Sutro Biopharma and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Sutro Biopharma's score of 0.93 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Sutro Biopharma Positive
Jyong Biotech Very Positive

Jyong Biotech has lower revenue, but higher earnings than Sutro Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$102.48M4.93-$191.09M-$11.04N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

97.0% of Sutro Biopharma shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Sutro Biopharma beats Jyong Biotech on 8 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to Cabaletta Bio?

Jyong Biotech (NASDAQ:MENS) and Cabaletta Bio (NASDAQ:CABA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Cabaletta Bio has a consensus target price of $15.50, suggesting a potential upside of 409.87%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cabaletta Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jyong BiotechN/AN/A-$4.67MN/AN/A
Cabaletta BioN/AN/A-$167.86M-$1.96N/A

In the previous week, Cabaletta Bio had 2 more articles in the media than Jyong Biotech. MarketBeat recorded 3 mentions for Cabaletta Bio and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Cabaletta Bio's score of 0.94 indicating that Jyong Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Jyong Biotech Very Positive
Cabaletta Bio Positive

Jyong Biotech's return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Jyong BiotechN/A N/A N/A
Cabaletta Bio N/A -131.58%-96.46%

Summary

Jyong Biotech and Cabaletta Bio tied by winning 4 of the 8 factors compared between the two stocks.

How does Jyong Biotech compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

95.2% of Arvinas shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arvinas had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Arvinas and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Arvinas' score of 0.70 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Arvinas Positive
Jyong Biotech Very Positive

Jyong Biotech has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Jyong Biotech's return on equity of 0.00% beat Arvinas' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-247.54% -44.38% -28.38%
Jyong Biotech N/A N/A N/A

Jyong Biotech has lower revenue, but higher earnings than Arvinas.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$262.60M1.97-$80.80M-$3.32N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

Arvinas currently has a consensus price target of $15.42, indicating a potential upside of 91.87%. Given Arvinas' stronger consensus rating and higher possible upside, research analysts clearly believe Arvinas is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
2 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.46
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Arvinas beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Jyong Biotech compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$29.44M-$0.92N/A
Jyong BiotechN/AN/A-$4.67MN/AN/A

Immix Biopharma currently has a consensus price target of $20.67, suggesting a potential upside of 107.08%. Given Immix Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Immix Biopharma is more favorable than Jyong Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Jyong Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Immix Biopharma had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Immix Biopharma and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Immix Biopharma's score of 1.33 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Immix Biopharma Positive
Jyong Biotech Very Positive

11.3% of Immix Biopharma shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jyong Biotech's return on equity of 0.00% beat Immix Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -73.24% -59.20%
Jyong Biotech N/A N/A N/A

Summary

Immix Biopharma beats Jyong Biotech on 6 of the 10 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MENS vs. The Competition

Export
MetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$144.45M$979.79M$4.35B$12.17B
Dividend YieldN/A4.84%11.53%5.91%
P/E RatioN/A1.5022.0124.19
Price / SalesN/A129.09202.5082.79
Price / CashN/A20.0638.0153.91
Price / Book-5.708.0113.626.37
Net Income-$4.67M-$4.05M$115.37M$337.69M
7 Day Performance20.51%0.56%-1.12%-0.30%
1 Month Performance-13.36%1.25%-2.51%0.36%
1 Year PerformanceN/A47.33%10.88%26.94%

Jyong Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MENS
Jyong Biotech
N/A$1.88
-1.1%		N/AN/A$144.45MN/AN/A31
KYTX
Kyverna Therapeutics
2.6213 of 5 stars		$7.89
-3.2%		$30.00
+280.2%		+167.1%$479.63MN/AN/A96
STRO
Sutro Biopharma
3.1362 of 5 stars		$28.73
-4.9%		$52.44
+82.5%		+266.9%$478.29M$102.48MN/A240
CABA
Cabaletta Bio
2.4365 of 5 stars		$2.93
-2.8%		$15.50
+429.9%		+65.0%$476.92MN/AN/A50
ARVN
Arvinas
2.9337 of 5 stars		$7.38
-1.5%		$15.42
+109.0%		+2.9%$475.84M$262.60MN/A420

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
Problems at SpaceX: time to get out?
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)
The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...
Brownstone Research | Sponsoredtc pixel